The Effects of Biotouch on
Prothrombotic, Antithrombotic,
Inflammatory, Neuroendocrine, and
Immune Signaling
Factors in Postmenopausal Women.
Preliminary results presented by
Kenna Stephenson, M.D.
April 2004
University of Texas Health Center-Tyler
Stephenson, Neuenschwander, Kurdowska,
Creech, UTHC-Tyler.
Edited by Jennifer Phelps
As I’m getting ready to write the paper
from this project I’ve been looking at the literature. Some of you may be familiar
with the animal world. What is one thing we always see in rodents and with the
higher primates? It’s touching. You can’t have 2 animals together for very long
without them touching each other. There is just something inherent in then,
instinctual, that makes them want to touch and be touched. We know from rodent
studies that when a mouse or a hamster is touched, oxytosin, a neurohormome is
released. That has a feel-good type of action in the brain but it also induces
touch, makes them want to touch another. We also know that is you isolate
monkeys and you deprive them of touch, they suffer. They suffer tremendously,
not just physically but also emotionally.
I think that we may be similar to the
animals in our need to touch and be touched. There is a physician at
Our skin is our
largest organ but, as physicians, we often overlook the skin as being useful
for therapeutic modalities. For instance, skin diseases like herpes, shingles,
psoriasis, dermatitis; when do they flare? When the patient is stressed. It
makes sense to me that something that touches the skin can induce changes and
have a healing effect on the body.
We know that with aging there are changes
in the inflammatory pathways and in immune response that make people more at
risk for cardiovascular events or for cancer to occur. We’re hoping to prevent
these types of problems, quite possibly, with something like Bio-Touch.
We enrolled 18 postmenopausal women in the first
part of the study. We had 9 in the Control group and 9 in the Bio-Touch group
and studied blood work and saliva tests in both groups. These are preliminary
results. We have, I think, 486 samples still at the lab right now, but I was
eager to go ahead and share the results that we have because I think they’re
very important.
This
is what we were looking at:
Interleukin-12
(IL-12) is a substance in the body that helps kill tumor cells. As IL-12
levels go down with age, the potential for tumor growth increases. We know
especially that breast cancer patients have low IL-12 levels. The potential for
mutations in genes to group together into a mass or tumor and develop blood
vessels to feed themselves can flourish in an environment of low IL-12. Also, asthma patients, people with sever
allergies, have low IL-12.
Researchers have tried to raise IL-12
levels using high doses of Vitamin C and Vitamin E, but they have not been
successful. They’ve also tried giving people synthetic IL-12, especially cancer
patients, but it’s very toxic, hard for the patient to tolerate. This is of
tremendous importance. Keeping IL-12 levels up is an effect that could quite
possibly be preventive or protective over time.
What we discovered was that the Control
group had appropriately low IL-12 levels for their age, while the Bio-Touch group
had an increase in their IL-12 levels.
Another finding is that something called Myeloperoxidase goes down in the
Bio-Touch group; whereas we see the age-related increase in Myeloperoxidase in
the Control group. [High levels of Myeloperoxidase indicate risk of
cardiovascular disease; also a good biomarker for autoimmune, inflammatory
diseases and cancer.]
Also we know that a high nighttime Cortisol [the primary stress hormone] is
associated with problems with glucose-insulin balance, with cancer risk, and
with cardiovascular disease risk. We saw that Bio-Touch tended to lower high
nighttime Cortisol to either close-to-normal or normal; whereas we saw no
change in the Control group.
My colleague Dr. Kurdowska took white blood
cells called Neutrophils from both
groups. She incubated and then stimulated
them, creating a sensation that might occur in the face of a virus or bacteria
being introduced into the body. She measured how quickly the blood cells acted
to respond to the bacteria or the virus and saw an enhanced neutrophil function
in the Bio-Touch group, as compared to our Control group. So people might be
less prone to infections or tend to have fewer infections with this type of
enhanced neutrophil function.
We were also looked at some Clotting Factors and saw no changes in
either group.
Concerning Hormone results, we not only looked at Cortisol, but we also looked
at testosterone, estrogen and progesterone. However, our limitation in
analyzing that data is financial. Subjects may be called upon later to complete
this part of the study as funding become available. Right now we’re now
analyzing the data on just 4 subjects to see which direction we want to pursue.
Finally, concerning the Genetic data, I’m hopeful we’ll have
that analyzed in the next 30 days, as I found a software program that will
allow me to mine the data with some expertise. [We’re hoping to see a notable
gene receptor response to Bio-Touch.]